R50CA292121
Project Grant
Overview
Grant Description
Expanding access to perioperative and repurposed drug trials in melanoma and other solid tumors - Project summary
Michael Lowe, MD, MA, Associate Professor of Surgery and Director of the Melanoma Program at Winship Cancer Institute, seeks additional support to advance the institution’s participation in NCI-sponsored clinical trials.
His ongoing contributions, trajectory of trial participation, emerging leadership, and exciting ideas make him an indispensable asset to Winship’s NTCN participation.
Dr. Lowe is quickly becoming a nationally recognized leader in surgical oncology and cutaneous malignancies, and he is driven to bring as many concepts as possible through the NCI Cooperative Group mechanism.
He is a member of the Winship Clinical Council and Protocol Review and Monitoring Committee and serves as the Director of the Melanoma Program and Chair of the Melanoma Working Group.
He is Clinical Director of the Morningside Center for Innovative and Affordable Medicine, which sponsors clinical trials investigating repurposed drugs in cancer.
He is a member of the ECOG-ACRIN Melanoma and Surgical Committees and serves as the ECOG-ACRIN liaison to the SWOG Melanoma Committee and the liaison of the Melanoma Committee to the Surgery Committee.
He is Surgical Chair of three NCTN clinical trials (EA6183, EA6212, and S1801) and is the ECOG Champion of S2015.
He serves as Site PI of S1801 and S2015 and is one of the highest NCTN enrolling investigators at Winship.
He is also Site PI of numerous investigator-initiated and industry-sponsored clinical trials.
Dr. Lowe has established himself as a dedicated researcher with a special interest in advancing concepts through the NCTN Cooperative Group mechanism.
Over the next five years with support from this grant, he plans to increase institutional participation in NCI-supported research and personally propose and develop two specific trials.
He will advocate for less traditional clinical trialists like surgeons, radiation oncologists, radiologists, and dermatologists to participate in the NCTN trials.
Dr. Lowe will also strongly advocate to NCTN leadership to implement a more systemic process of patient engagement in the design of NCI-supported trials, including patient-centered focus groups and/or surveys designed to assess the patient’s perspective on the trial design.
Given his experience in repurposed drug trials, he will advocate for disease-specific repurposed drug trials to be opened in the NCTN committees and work towards developing a repurposed drug subcommittee within NCTN.
Lastly, Dr. Lowe will work with Winship CTO leadership to identify causes of NCTN trial opening delays and work on solutions to resolve them.
He is motivated to make an even bigger impact through NCI-supported research, and this award would make a considerable impact on his ability to do so.
His passion for improving the lives of patients through clinical research makes his potential capabilities limitless, and providing the additional time provided by this award will help maximize that potential.
Michael Lowe, MD, MA, Associate Professor of Surgery and Director of the Melanoma Program at Winship Cancer Institute, seeks additional support to advance the institution’s participation in NCI-sponsored clinical trials.
His ongoing contributions, trajectory of trial participation, emerging leadership, and exciting ideas make him an indispensable asset to Winship’s NTCN participation.
Dr. Lowe is quickly becoming a nationally recognized leader in surgical oncology and cutaneous malignancies, and he is driven to bring as many concepts as possible through the NCI Cooperative Group mechanism.
He is a member of the Winship Clinical Council and Protocol Review and Monitoring Committee and serves as the Director of the Melanoma Program and Chair of the Melanoma Working Group.
He is Clinical Director of the Morningside Center for Innovative and Affordable Medicine, which sponsors clinical trials investigating repurposed drugs in cancer.
He is a member of the ECOG-ACRIN Melanoma and Surgical Committees and serves as the ECOG-ACRIN liaison to the SWOG Melanoma Committee and the liaison of the Melanoma Committee to the Surgery Committee.
He is Surgical Chair of three NCTN clinical trials (EA6183, EA6212, and S1801) and is the ECOG Champion of S2015.
He serves as Site PI of S1801 and S2015 and is one of the highest NCTN enrolling investigators at Winship.
He is also Site PI of numerous investigator-initiated and industry-sponsored clinical trials.
Dr. Lowe has established himself as a dedicated researcher with a special interest in advancing concepts through the NCTN Cooperative Group mechanism.
Over the next five years with support from this grant, he plans to increase institutional participation in NCI-supported research and personally propose and develop two specific trials.
He will advocate for less traditional clinical trialists like surgeons, radiation oncologists, radiologists, and dermatologists to participate in the NCTN trials.
Dr. Lowe will also strongly advocate to NCTN leadership to implement a more systemic process of patient engagement in the design of NCI-supported trials, including patient-centered focus groups and/or surveys designed to assess the patient’s perspective on the trial design.
Given his experience in repurposed drug trials, he will advocate for disease-specific repurposed drug trials to be opened in the NCTN committees and work towards developing a repurposed drug subcommittee within NCTN.
Lastly, Dr. Lowe will work with Winship CTO leadership to identify causes of NCTN trial opening delays and work on solutions to resolve them.
He is motivated to make an even bigger impact through NCI-supported research, and this award would make a considerable impact on his ability to do so.
His passion for improving the lives of patients through clinical research makes his potential capabilities limitless, and providing the additional time provided by this award will help maximize that potential.
Awardee
Funding Goals
TO DEVELOP THE MEANS TO CURE AS MANY CANCER PATIENTS AS POSSIBLE AND TO CONTROL THE DISEASE IN THOSE PATIENTS WHO ARE NOT CURED. CANCER TREATMENT RESEARCH INCLUDES THE DEVELOPMENT AND EVALUATION OF IMPROVED METHODS OF CANCER TREATMENT THROUGH THE SUPPORT AND PERFORMANCE OF BOTH FUNDAMENTAL AND APPLIED LABORATORY AND CLINICAL RESEARCH. RESEARCH IS SUPPORTED IN THE DISCOVERY, DEVELOPMENT, AND CLINICAL TESTING OF ALL MODES OF THERAPY INCLUDING: SURGERY, RADIOTHERAPY, CHEMOTHERAPY, AND BIOLOGICAL THERAPY INCLUDING MOLECULARLY TARGETED THERAPIES, BOTH INDIVIDUALLY AND IN COMBINATION. IN ADDITION, RESEARCH IS CARRIED OUT IN AREAS OF NUTRITIONAL SUPPORT, STEM CELL AND BONE MARROW TRANSPLANTATION, IMAGE GUIDED THERAPIES AND STUDIES TO REDUCE TOXICITY OF CYTOTOXIC THERAPIES, AND OTHER METHODS OF SUPPORTIVE CARE THAT MAY SUPPLEMENT AND ENHANCE PRIMARY TREATMENT. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Georgia
United States
Geographic Scope
State-Wide
Emory University was awarded
Project Grant R50CA292121
worth $83,925
from National Cancer Institute in September 2025 with work to be completed primarily in Georgia United States.
The grant
has a duration of 5 years and
was awarded through assistance program 93.395 Cancer Treatment Research.
The Project Grant was awarded through grant opportunity NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed).
Status
(Ongoing)
Last Modified 9/24/25
Period of Performance
9/10/25
Start Date
8/31/30
End Date
Funding Split
$83.9K
Federal Obligation
$0.0
Non-Federal Obligation
$83.9K
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
R50CA292121
SAI Number
R50CA292121-1224302129
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75NC00 NIH National Cancer Institute
Funding Office
75NC00 NIH National Cancer Institute
Awardee UEI
S352L5PJLMP8
Awardee CAGE
2K291
Performance District
GA-90
Senators
Jon Ossoff
Raphael Warnock
Raphael Warnock
Modified: 9/24/25